ADO

Anteotech

Pharmaceuticals, Biotechnology & Life Sciences

Anteotech Ltd specializes in the development and commercialization of advanced medical diagnostics and energy storage solutions, leveraging its proprietary nanotechnology platform. It operates in healthcare and energy sectors, aiming for a significant market position through innovative solutions such as its proprietary AnteoBind™ technology, which enhances the sensitivity and performance of diagno...

pharmaceutical

biotechnology

medical devices

energy storage

Shorted

short percentage0.56%

reported shorts15.3M

shares on issue2.727B

About

website

anteotech.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Unit 4, 26 Brandl Street, Eight Mile Plains, QLD, AUSTRALIA, 4113

Connect

Key Metrics

market cap

$38.18M

price$0.01

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

pharmaceutical

biotechnology

medical devices

energy storage

nanotechnology

Company Overview

AI-generated company summary

Company History

Anteotech Ltd was founded in 1999 and has since evolved from its origins in biotechnology to incorporate a robust portfolio of products in medical diagnostics and energy technologies. A significant milestone was its rebranding from Bio-Layer Corporation to Anteotech and its strategic pivot towards nanotechnology applications. The company went public on the ASX, which has enabled it to raise capital for R&D and commercialization efforts.

Competitive Advantages

Anteotech leverages its proprietary AnteoBind™ technology, providing competitive advantages in enhancing the sensitivity and accuracy of diagnostic tests. Its strategic focus on both the healthcare and energy sectors diversifies revenue streams, reducing dependency on a single market. Collaborations with leading industry partners amplify its market access and technological validation.

Risk Factors

•Early-stage technology adoption challenges
•Regulatory hurdles in different jurisdictions
•Dependence on strategic partnerships for market penetration
•Volatility in raw material prices impacting production costs

Recent Developments

Last 6 months

In the past six months, Anteotech announced significant progress in its COVID-19 Rapid Test Portfolio, aiming for market approval across various regions. They have also been expanding their energy storage business through strategic partnerships and technology advancements, positioning themselves to capture emerging market opportunities in renewable energy applications.

Key People

Leadership team at Anteotech

Derek Thomson

CEO

Derek Thomson was appointed as CEO of Anteotech in 2022. He brings extensive experience in science commercialization and management, having held senior positions in various technology and life science companies.

Candice Amery

CFO

Candice Amery joined Anteotech as CFO in 2021. She has a strong background in financial management and corporate governance, with previous roles in the financial services and biotechnology sectors.

Financial Reports

19 reports available

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportOct 27, 2025via asx_announcements

Full Year Results and Business Update Presentation

Full Year ResultsAug 28, 2025via asx_announcements

FY2025 Full Year Appendix 4E and Annual Report

Annual ResultsAug 27, 2025via asx_announcements

Full Year Results Timing & Investor Call

Full Year ResultsAug 14, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportJul 30, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportApr 30, 2025via asx_announcements

Half Year Results and Operational Update Presentation

Half Year ResultsFeb 26, 2025via asx_announcements

Half Yearly Report and Accounts

Half Year ResultsFeb 26, 2025via asx_announcements

Half Yearly Results Timing & Investor Update Call

Half Year ResultsFeb 12, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportJan 28, 2025via asx_announcements

Showing 10 of 19 reports